Get the Stockscreener App
1.03
0.96%
-0.01
Calidi Biotherapeutics Inc stock is traded at $1.03, with a volume of 17,881.
It is down -0.96% in the last 24 hours and down -24.26% over the past month.
Calidi Biotherapeutics Inc., a clinical stage immuno-oncology company, engages in developing immunotherapies for the treatment of cancer. It engages in advancing a potent allogeneic stem cell capable of carrying an anti-tumor payload for use in multiple oncology indications, including high-grade gliomas and solid tumors. The company's cell-based delivery platforms are designed to protect, amplify, and potentiate oncolytic viruses leading to enhanced efficacy and improved patient safety. Its pipeline of products candidates in the clinic includes NeuroNova that are allogeneic neural stem cells loaded with an oncolytic adenovirus for the treatment of high-grade gliomas; and SuperNova, which are allogeneic adipose-derived mesenchymal stem cells loaded with tumor-selective CAL1 oncolytic vaccinia virus for the treatment of advanced metastatic solid tumors. The company was founded in 2014 and is headquartered in San Diego, California.
See More
Previous Close:
$1.04
Open:
$1.04
24h Volume:
17,881
Relative Volume:
0.37
Market Cap:
$2.66M
Revenue:
Net Income/Loss:
$-25.09M
P/E Ratio:
-0.1987
EPS:
-5.1824
Net Cash Flow:
$-18.40M
1W Performance:
-4.63%
1M Performance:
-24.26%
6M Performance:
-75.01%
1Y Performance:
-95.95%
1-Day Range:
$1.03
$1.05
1-Week Range:
$0.986
$1.1199
52-Week Range:
$0.986
$27.84
Calidi Biotherapeutics Inc Stock (CLDI) Company Profile
Name
Calidi Biotherapeutics Inc
Sector
Industry
Phone
(858) 794-9600
Address
4475 Executive Drive, Suite 200, San Diego
Compare CLDI vs VRTX, MRNA, REGN, ARGX, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CLDI
Calidi Biotherapeutics Inc
|
1.03 | 2.66M | 0 | -25.09M | -18.40M | -5.1824 |
VRTX
Vertex Pharmaceuticals Inc
|
510.08 | 129.29B | 12.34B | 4.34B | 3.71B | 16.87 |
MRNA
Moderna Inc
|
225.00 | 89.83B | 2.23B | -3.19B | -1.60B | -8.1462 |
REGN
Regeneron Pharmaceuticals Inc
|
746.54 | 76.86B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
825.03 | 51.88B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
189.76 | 40.67B | 742.00K | -1.37B | -1.07B | -7.0731 |
Calidi Biotherapeutics Inc Stock (CLDI) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-22-23 | Initiated | H.C. Wainwright | Buy |
| Oct-09-23 | Initiated | Robert W. Baird | Outperform |
Calidi Biotherapeutics Inc Stock (CLDI) Latest News
Enterprise value to EBITDA forward of Calidi Biotherapeutics Inc. – OTC:CLDWW - TradingView
Calidi Biotherapeutics (NYSEAMERICAN:CLDI) Races to Fix an Equity Shortfall Before Delisting - kalkine.ca
Calidi Biotherapeutics Received Notice of Noncompliance - TradingView
Calidi Biotherapeutics Received NYSE American Notification Letter Regarding Stockholders’ Equity Deficiency - GlobeNewswire Inc.
Calidi Biotherapeutics Received NYSE American Notification Letter Regarding Stockholders’ Equity Deficiency - GlobeNewswire
Calidi Biotherapeutics Finalizes $1.2M Registered Direct Stock Offering - Kalkine Media
Calidi Biotherapeutics Raises $1.2 Million in Registered Direct Offering at $1.17 Per Share - tradingview.com
Calidi Biotherapeutics Announces $1.2 Million Registered Direct Offering - Quiver Quantitative
Calidi Biotherapeutics Announces $1.2 Million Registered Direct Offering - GlobeNewswire
A biotech plans to raise about $1.2 million by selling shares at $1.17 each. - Stock Titan
Calidi Biotherapeutics Announces $1.2 Million Registered Direct Offering - Yahoo Finance
Calidi Biotherapeutics to Participate in the H.C. Wainwright 28th Annual Global Investment Conference - GlobeNewswire
Calidi Biotherapeutics to Participate in the H.C. Wainwright 28th Annual Global Investment Conference - Yahoo Finance
CLDI Q4 2025 Earnings: Loss Narrows Sharply, Beating Estimates by 73.59%; Shares Rise 3.41%Dividend Earnings Report - vinanet.vn
ARMISTICE CAPITAL, LLC Slashes Calidi Biotherapeutics (CLDI) Sta - GuruFocus
Calidi (CLDI) Quarterly Scorecard: EPS Exceeds Its Estimate in Latest Trading; Market Response: Shares Move Lower 2.90%Dividend Cut Risk - vinanet.vn
Calidi Biotherapeutics (CLDI) grants director 5,000 options - Stock Titan
Calidi director granted 4,000 options at $1.36 | CLDI Insider Trading - Stock Titan
Calidi Biotherapeutics (CLDI) gives CFO 14,000 options with 10-year term - Stock Titan
Calidi Biotherapeutics (CLDI) awards director 4,000 options vesting in 1 year - Stock Titan
Calidi Biotherapeutics (CLDI) CEO awarded 32K options vesting over 4 years - Stock Titan
Calidi Biotherapeutics (CLDI) awards 16,000 options to CSO - Stock Titan
Calidi (CLDI) Report Card: The EPS Result Is Above Expectation in the Current Update; Reaction Snapshot: Shares Close 6.62% Lower in the Latest SessionTrough Earnings Signal - vinanet.vn
Calidi (CLDI) Closing Snapshot: Retreats 5.59% to $1.28 in the Current Update; Technical Position: the Near-Term Reference Band Stretches From $1.22 to $1.34 on the DayCalendar Spread Trade - vinanet.vn
Calidi Biotherapeutics Granted Patent for Cell-Based Oncolytic Virus Immunotherapy for Cancer Treatment - ACCESS Newswire
Armistice Capital reports 4.99% Calidi Biotherapeutics (CLDI) stake in Schedule 13G/A - Stock Titan
Form 8K Calidi Biotherapeutics Inc For: 13 August By Investing.com - Investing.com Nigeria
Calidi Biotherapeutics Reports Quarterly Results and Pipeline Progress - TipRanks
Calidi Biotherapeutics Q2 net loss narrows to $4.2M; G&A cuts 48% - scanx.trade
Calidi Biotherapeutics 2Q 2026: Net loss $4.16M, EPS $(2.94) — 10-Q Summary - TradingView
Form 8K Calidi Biotherapeutics Inc For: 13 August By Investing.com - Investing.com Canada
Form 8K Calidi Biotherapeutics Inc For: 13 August By Investing.com - Investing.com India
Calidi Biotherapeutics Reports Positive FDA Pre-IND Feedback for CLD-401, Showcases RedTail Platform Data and Cuts G&A Expenses - Quiver Quantitative
Calidi Biotherapeutics Reports Second Quarter 2026 Financial Results and Recent Business Highlights - Yahoo Finance
Calidi Biotherapeutics Reports Second Quarter 2026 Financial Results and Recent Business Highlights - GlobeNewswire
Price to book forward of Calidi Biotherapeutics Inc. – OTC:CLDWW - TradingView
Price to sales forward of Calidi Biotherapeutics Inc. – OTC:CLDWW - TradingView
Calidi Biotherapeutics (CLDI) Holds Steady at $1.63 as Stock Sits Between Support and ResistanceEntry Point Alerts - dars.gov.et
CLDI Q4 2025 Earnings: Narrower Loss of -$0.43 Per Share Beats Estimates, Stock Falls 9.5%High Estimate Range - vinanet.vn
Calidi Biotherapeutics (CLDI) Insider Trading Activity 2026 $CLDI - MarketBeat
Calidi Biotherapeutics Inc (CLDI) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Calidi Biotherapeutics (CLDI) Falls 6.88% to $1.76, Pressing Key Support at $1.67Straddle Setup - vinanet.vn
Calidi Biotherapeutics (CLDI) Jumps 12.5% to $1.89 as Bullish Momentum Builds Toward $1.98 ResistanceSector Neutral Pair - vinanet.vn
Price to sales forward of Calidi Biotherapeutics, Inc. – BOATS:CLDI - TradingView
Calidi Biotherapeutics Inc. (NYSE: CLDI) Share Price, CLDI Stock News, CLDI Share Price & Updates - Kalkine
Calidi Biotherapeutics (CLDI) Surges 9.86% to $1.64 as Buying Pressure BuildsGolden Cross - vinanet.vn
Calidi Biotherapeutics (CLDI) Surges 9.86% to $1.64 as Buying Pressure BuildsValue Stock Ideas - careplusvn.com
Calidi Biotherapeutics Announces Reverse Stock Split to Maintain NYSE American Listing – July 2026 8-K Filing - Minichart
Calidi Biotherapeutics Implements Reverse Stock Split on NYSE - TipRanks
Price to book forward of Calidi Biotherapeutics, Inc. – AMEX:CLDI - TradingView
Calidi Biotherapeutics Inc Stock (CLDI) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.64%
0.29%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):